Поиск патентов

05-01-2012 дата публикации

Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase

Номер: US20120003156A1

Автор: Chi V. Dang, Quy H. Le, Ramani Dinavahi

Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions for the diagnosis or treatment of neoplasias, including lymphomas, leukemias, brain cancers (e. glioblastomas, medulloblastomas), breast cancer, colon cancer, and pancreatic cancer, and methods of use therefor.

Подробнее

Номер записи: 1

05-01-2012 дата публикации

Methods and compositions for modulating proline levels

Номер: US20120003207A1

Автор: Mike A. Clark

Принадлежит: ONCOPHARMACOLOGICS Inc

Methods and compositions for modulating amino acid levels in a subject are provided herein.

Подробнее

Номер записи: 2

05-01-2012 дата публикации

Recombinant fusion protein and polynucleotide construct for immunotoxin production

Номер: US20120003223A1

Автор: Itai Benhar, Yariv Mazor

Принадлежит: Ramot at Tel Aviv University Ltd

The present invention relates to a polynucleotide construct encoding a fusion protein consisting of a domain which binds the immunoglobulin Fc region, genetically fused to a truncated form of Pseudomonas exotoxin A (PE). In particular, the invention discloses the fusion protein, ZZ-PE38, and further provides immunotoxins, formed from complexes of the fusion protein with antibodies for targeted cell killing.

Подробнее

Номер записи: 3

05-01-2012 дата публикации

Solid Dosage Forms Of Bendamustine

Номер: US20120003309A1

Автор: Jeffrey Colledge, Margaretha Olthoff, Taoufik Ouatas, Thomas Alfred Profitlich, Ulrich Patzak

Принадлежит: ASTELLAS DEUTSCHLAND GMBH

In the present invention there is provided a pharmaceutical composition in a solid dosage form suitable for oral administration, the composition comprising bendamustine or a pharmaceutically acceptable ester, salt or solvate thereof as an active ingredient, and at least one pharmaceutically acceptable excipient, which is a pharmaceutically acceptable saccharide selected from the group consisting of one or more of a monosaccharide, a disaccharide, an oligosaccharide, a cyclic oligosaccharide, a polysaccharide and a saccharide alcohol, wherein the ratio by weight of the active ingredient to the saccharide excipient(s) is in the range of 1:1-5.

Подробнее

Номер записи: 4

05-01-2012 дата публикации

Method of reducing multi-drug resistance using inositol tripyrophosphate

Номер: US20120003327A1

Автор: Claudine Kieda, Jean-Marie Lehn, Yves Claude Nicolau

Принадлежит: Individual

Inositol trisphosphate (ITPP) causes normalization of tumor vasculature and is a particularly effective cancer therapy when a second chemotherapeutic agent is administered following partial vascularization. ITPP also treats, alone or in combination, multi-drug resistant cancers. ITPP can also be used to reduce the amount of a second chemotherapeutic drug required for anticancer activity. In addition, ITPP enhances immune response and treats hyperproliferative disorders.

Подробнее

Номер записи: 5

05-01-2012 дата публикации

Biological control of nanoparticle nucleation, shape and crystal phase

Номер: US20120003629A9

Автор: Angela Belcher, Esther Ryan, Richard Smalley, Seung-Wuk Lee

Принадлежит: University of Texas System

The present invention includes compositions and methods for selective binding of amino acid oligomers to semiconductor and elemental carbon-containing materials. One form of the present invention is a method for controlling the particle size of the semiconductor or elemental carbon-containing material by interacting an amino acid oligomer that specifically binds the material with solutions that can result in the formation of the material. The same method can be used to control the aspect ratio of the nanocrystal particles of the semiconductor material. Another form of the present invention is a method to create nanowires from the semiconductor or elemental carbon-containing material. Yet another form of the present invention is a biologic scaffold comprising a substrate capable of binding one or more biologic materials, one or more biologic materials attached to the substrate, and one or more elemental carbon-containing molecules attached to one or more biologic materials.

Подробнее

Номер записи: 6

05-01-2012 дата публикации

Biomarkers for inhibitors with anti-angiogenic activity

Номер: US20120004129A1

Автор: Joyce Behrens

Принадлежит: Merck Patent GmBH

The invention relates to a method for assessing the effect of integrin inhibitors and small molecule ATP site directed multi kinase inhibitors on angiogenesis by the use of certain identified biomarkers. This method is notably beneficial for the determination of the efficacy of integrin inhibitors and small molecule ATP site directed multi-kinase inhibitors mainly used for the treatment of angiogenesis associated diseases such as cancer. Especially, the invention relates to biomarkers linked to angiogenesis that are preferably accessible in body fluids and therefore allow analysis of target modulation in a non-invasive way. The use of said biomarkers for the screening of compounds with integrin-inhibitory activity is also disclosed.

Подробнее

Номер записи: 7

05-01-2012 дата публикации

Materials and methods for treatment of cancer and identification of anti-cancer compounds

Номер: US20120004169A1

Автор: Richard Jove, Said M. Sebti

Принадлежит: UNIVERSITY OF SOUTH FLORIDA

The subject invention pertains to the treatment of tumors and cancerous tissues and the prevention of tumorigenesis and malignant transformation through the modulation of JAK/STAT3 intracellular signaling. The subject invention concerns pharmaceutical compositions containing cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the invention concerns methods of inhibiting the growth of a tumor by administering a cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof, to a patient, wherein the tumor is characterized by the constitutive activation of the JAK/STAT3 intracellular signaling pathway. The present invention further pertains to methods of moderating the JAK and/or STAT3 signaling pathways in vitro or in vivo using cucurbitacin I, or a pharmaceutically acceptable salt or analog thereof. Another aspect of the present invention concerns a method for screening candidate compounds for JAK and/or STAT3 inhibition and anti-tumor activity.

Подробнее

Номер записи: 8

05-01-2012 дата публикации

Modulators of atp-binding cassette transporters

Номер: US20120004216A1

Автор: Ashvani K. Singh, Lewis R. Makings, Mark T. Miller, Matthew Hamilton, Peter D.J. Grootenhuis, Sara S. Hadida Ruah, Thomas Cleveland

Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including CF Transmembrane Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Подробнее

Номер записи: 9

05-01-2012 дата публикации

Novel tetrahydro-quinoline derivatives

Номер: US20120004218A1

Автор: HongYing Yun, Li Chen, Lichun Feng, Mengwei Huang, Mingwei Zhou, Yongfu Liu, Yun He

Принадлежит: Hoffmann La Roche Inc

A compound of formula (I) or a pharmaceutically acceptable salt or ester thereof, wherein A 1 to A 3 and R 1 to R 10 have the significance given in claim 1 , can be used as a medicament. These compounds are useful in the treatment or prophylaxis of diseases that are related to AMPK regulation, such as obesity, dyslipidemia, hyperglycemia, type 1 or type 2 diabetes and cancers.

Подробнее

Номер записи: 10

05-01-2012 дата публикации

Triheterocyclic Compounds and Compositions Thereof

Номер: US20120004224A1

Автор: Elisc Rioux, Giorgio Attardo, Jean-Francois Lavallee, Sasmita Tripathy, Terrance W. Deyle

Принадлежит: Gemin X Pharmaceuticals Canada Inc

The present invention relates to novel Triheterocyclic Compounds, compositions comprising a Triheterocyclic Compound, and methods useful for treating or preventing cancer or a neoplastic disorder comprising administering a Triheterocyclic Compound. The compounds, compositions, and methods of the invention are also useful for inhibiting the growth of a cancer cell or neoplastic cell, treating or preventing a viral infection, or inhibiting the replication and/or infectivity of a virus.

Подробнее

Номер записи: 11

05-01-2012 дата публикации

Compounds for the treatment of pathologies associated with aging and degenerative disorders

Номер: US20120004263A1

Автор: Laura J. Niedernhofer, Paul D. Robbins, Peter Wipf

Принадлежит: University of Pittsburgh

The present invention relates to methods of inhibiting one or more signs of aging and/or degenerative disorder in a subject in need of such treatment, which comprise administering, to the subject, an effective amount of one or more of the compounds as set forth herein. “Inhibiting a sign of aging or degenerative disorder” means reducing the risk of occurrence, delaying the onset, slowing the progression, and/or reducing the severity and/or manifestation, of a sign of aging or degenerative disorder, and includes, but is not limited to, preventing the occurrence, development or progression of a sign of aging or degenerative disorder.

Подробнее

Номер записи: 12

05-01-2012 дата публикации

Chroman derivatives, medicaments and use in therapy

Номер: US20120004296A1

Автор: Alan Husband, Andrew Heaton

Принадлежит: Marshall Edwards Inc

Novel chroman derivatives and intermediate compounds, compositions containing same, methods for their preparation and uses thereof as therapeutic agents particularly as anti-cancer and chemotherapeutic selective agents are described.

Подробнее

Номер записи: 13

10-01-2017 дата публикации

Нанодиски для разрушения опухолевых клеток

Номер: RU0000167739U1

Автор: Замай Анна Сергеевна, Замай Галина Сергеевна, Замай Сергей Сергеевич, Замай Татьяна Николаевна, Ким Петр Дементьевич, Принц Виктор Яковлевич, Прокопенко Владимир Семенович, Селезнев Владимир Александрович

Принадлежит: Государственное бюджетное образовательное учреждение высшего профессионального образования "Красноярский государственный медицинский университет имени профессора В.Ф. Войно-Ясенецкого" Министерства здравоохранения Российской Федерации КрасГМУ (ГБОУ ВПО КрасГМУ им. проф. В.Ф. Войно-Ясенецкого Минздрава России), Федеральное государственное бюджетное учреждение науки Красноярский научный центр Сибирского отделения Российской академии наук (ФГБУН КНЦ СО РАН)

Полезная модель относится к области биотехнологии, а именно к нанодискам, применяемым для разрушения опухолевых клеток с помощью магнитного поля. Нанодиски для разрушения опухолевых клеток выполнены многослойными и включают слой из никеля 1, толщиной 50 нм, слои из золота 2, каждый из которых выполнен толщиной 50 нм покрывающие никелевый слой с обеих сторон, аптамеры 3, специфичные к опухолевой клетке, присоединенные к слоям золота посредством праймеров 4, содержащих SH группы. Нанодиски для разрушения опухолевых клеток эффективно работают в условиях переменного магнитного поля, оказывая разрушающее воздействие на клетки опухоли. 1 илл. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 167 739 U1 (51) МПК A61K 33/24 (2006.01) A61P 35/00 (2006.01) B82B 1/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (21)(22) Заявка: 2015151687, 02.12.2015 (24) Дата начала отсчета срока действия патента: 02.12.2015 Дата регистрации: Приоритет(ы): (22) Дата подачи заявки: 02.12.2015 (45) Опубликовано: 10.01.2017 Бюл. № 1 U 1 1 6 7 7 3 9 R U Biofunctionalized magnetic-vortex microdiscs for targeted cancer-cell destruction, Nature materials, 2010, v.9, p.165-171. RU 2524644 C2, 27.07.2014. Л.А. ДЫКМАН, Н.Г. ХЛЕБЦОВ "Золотые наночастицы в биологии и медицине: достижения поледних лет и перспективы", Acta Naturae (рускоязычная версия), т.3, N2(9), 2011, с.36-58. А.В. (см. прод.) (54) Нанодиски для разрушения опухолевых клеток (57) Реферат: Полезная модель относится к области биотехнологии, а именно к нанодискам, применяемым для разрушения опухолевых клеток с помощью магнитного поля. Стр.: 1 Нанодиски для разрушения опухолевых клеток выполнены многослойными и включают слой из никеля 1, толщиной 50 нм, слои из золота 2, каждый из которых выполнен толщиной 50 нм U 1 (56) Список документов, цитированных в отчете о поиске: Dong-Hyun Kim et al. 1 6 7 7 3 9 Адрес для переписки: 660036, г. Красноярск, Академгородок, 28, кв. 98, Замай Татьяне ...

Подробнее

Номер записи: 14

21-02-2020 дата публикации

НОСИТЕЛЬ ДЛЯ ДИАГНОСТИКИ, НАПРАВЛЕННОЙ ДОСТАВКИ И КОНТРОЛИРУЕМОГО ВЫСВОБОЖДЕНИЯ ЛЕКАРСТВЕННЫХ СРЕДСТВ

Номер: RU0000196226U1

Автор: Набиев Игорь Руфаилович, Нифонтова Галина Олеговна, Соколов Павел Михайлович

Принадлежит: Федеральное государственное автономное учреждение высшего образования "Национальный исследовательский ядерный университет "МИФИ" (НИЯУ МИФИ)

Полезная модель относится к области медицинских исследований и терапии онкологических заболеваний. Раскрыт носитель для направленной доставки и контролируемого высвобождения лекарственных средств, представляющий собой микрокапсулу, оболочка которой состоит из слоев полиэлектролитов, причем на поверхности внешнего слоя полиэлектролита иммобилизованы однодоменные антитела специфичные к маркерам онкологических заболеваний, а между слоями полиэлектролитов нанесен слой, включающий магнитные наночастицы, слой, включающий инфракрасные квантовые точки, а также слой, включающий плазмонные наночастицы, где слои инфракрасных квантовых точек, магнитных и плазмонных наночастиц разделены тремя чередующимися слоями полиэлектролитов разных зарядов, при этом сама оболочка выполнена с возможностью разрушения в ответ на излучение, а внутри микрокапсулы находится лекарственное средство. При этом на поверхности микрокапсулы находятся молекулы органического флуоресцентного красителя, соединенные с поверхностью микрокапсулы с помощью линкера, который обеспечивает сближение органического флуоресцентного красителя и квантовыми точками при изменении pH от нейтрального до слабокислотного, при этом органический флуоресцентный краситель и квантовые точки подобраны так, что спектр флуоресценции квантовых точек позволяет возбуждать флуоресценцию органического флуоресцентного красителя. Технический результат предлагаемой полезной модели заключается в снижении стоимости изготовления и использования носителя для диагностики, направленной доставки и контролируемого высвобождения лекарственных средств, а также повышению удобства использования, благодаря возможности детекции проникновения и накопления носителя внутри опухоли с помощью только оптических методов. 10 з.п. ф-лы, 1 ил. РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) RU (11) (13) 196 226 U1 (51) МПК A61K 49/08 (2006.01) A61K 9/50 (2006.01) A61P 35/00 (2006.01) ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ (12) ОПИСАНИЕ ПОЛЕЗНОЙ МОДЕЛИ К ПАТЕНТУ (52) СПК ...

Подробнее

Номер записи: 15

12-01-2012 дата публикации

Gastrin releasing peptide compounds

Номер: US20120009122A1

Автор: Adrian D. Nunn, Edmund Marinelli, Enrico Cappelletti, Karen E. Linder, Kondareddiar Ramalingam, Luciano Lattuada, Michael F. Tweedle, Natarajan Raju, Palaniappa Nanjappan, Rolf E. Swenson

Принадлежит: BRACCO IMAGING SPA

New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.

Подробнее

Номер записи: 16

12-01-2012 дата публикации

Compositions for bacterial mediated gene silencing and methods of using the same

Номер: US20120009153A1

Автор: Chiang J. Li, Hongnian Guo, Johannes Fruehauf

Принадлежит: Individual

The invention features compositions and methods for delivering small interfering (siRNAs), e.g., shRNAs, to host cells using non-pathogenic strains of Salmonella bacteria containing nucleic acid expression constructs encoding shRNAs. In this process, shRNA expressed by the Salmonella silences or knocks down genes of interest (target genes) inside target cells. The nucleic acid expression constructs of the invention include an RNA polymerase (e.g., a T7 polymerase), an RNA polymerase promoter (e.g., a T7 polymerase promoter), and an RNA polymerase terminator (e.g., a T7 polymerase terminator). The Salmonella bacteria can also include, on the same or different nucleic acid construct, an endosomal release factor (e.g., HlyA).

Подробнее

Номер записи: 17

12-01-2012 дата публикации

Renal cell carcinoma biomarkers

Номер: US20120009201A1

Автор: Bih-Rong Wei, Donald J. Johann, Josip Blonder, Timothy D. Veenstra

Принадлежит: US Department of Health and Human Services

Disclosed herein is a method of identifying a tumor biomarker. In one example, a tumor biomarker is identified by obtaining a peripheral biological fluid sample from a subject with a tumor as well as a tumor sample and an adjacent non-tumor sample from such subject. A protein expression profile is detected in the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample. The protein expression profiles of the peripheral biological fluid sample, tumor sample and adjacent non-tumor sample are then compared, wherein an increase in expression of a specific protein in the tumor sample and peripheral biological fluid sample but not in the adjacent non-tumor sample indicates that the specific protein is a biomarker of the tumor. Also disclosed herein is a gene profiling signature that can be used to diagnosis a subject with renal cell carcinoma (RCC) or to identify agents with therapeutic potential to treat RCC. Thus, methods of diagnosing a subject with RCC are disclosed. Methods are also provided for identifying agents that alter an activity of a RCC biomarker.

Подробнее

Номер записи: 18

12-01-2012 дата публикации

Monoparamunity inducers based on attenuated rabbit myxomaviruses

Номер: US20120009217A1

Автор: Anton Mayr, Barbara Mayr

Принадлежит: Individual

The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals.

Подробнее

Номер записи: 19

12-01-2012 дата публикации

Transfection of blood cells with mrna for immune stimulation and gene therapy

Номер: US20120009221A1

Автор: Florian Van Der Mülbe, Ingmar Hoerr, Steve Pascolo

Принадлежит: CureVac AG

The present invention relates to a pharmaceutical composition containing blood cells or haemopoietic cells, e.g. red blood cells (erythrocytes), granulocytes, mononuclear cells (PBMCs) and/or blood platelets, in combination with a pharmaceutically acceptable excipient and/or vehicle, wherein the cells are transfected with at least one mRNA comprising at least one region coding for at least one antigen. The invention further discloses a method of preparing the aforesaid pharmaceutical composition and the use of blood cells transfected in this way for the preparation of drugs or pharmaceutical compositions for immune stimulation against the antigens encoded by the mRNA. The subjects according to the invention are used especially for the therapy and/or prophylaxis of carcinoses or infectious diseases and can also be employed in gene therapy.

Подробнее

Номер записи: 20

12-01-2012 дата публикации

Modified Virus Vectors and Methods of Making and Using the Same

Номер: US20120009268A1

Автор: Aravind Asokan, Richard Jude Samulski

Принадлежит: UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL

The present invention provides AAV capsid proteins (VP1, VP2 and/or VP3) comprising a modification in the amino acid sequence in the three-fold axis loop 4 and virus capsids and virus vectors comprising the modified AAV capsid protein. In particular embodiments, the modification comprises a substitution of one or more amino acids at amino acid positions 585 to 590 (inclusive) of the native AAV2 capsid protein sequence or the corresponding positions of other AAV capsid proteins. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.

Подробнее

Номер записи: 21

12-01-2012 дата публикации

Cell Penetrating Peptide Conjugates for Delivering of Nucleic Acids into a Cell

Номер: US20120010124A9

Автор: Bertrand Alluis, Jean-Sebastien Fruchart

Принадлежит: Diatos SA

The invention provides cell penetrating peptide-nucleic acid conjugates having the formula P-L-N, wherein P is a cell penetrating peptide, N is a nucleic acid, preferably an oligonucleotide and more preferably a siRNA, and L is a hydrophilic polymer, preferably a polyethylene glycol (PEG)-based linker linking P and N together. Compositions, methods of use and methods for producing such conjugates are also disclosed.

Подробнее

Номер записи: 22

12-01-2012 дата публикации

Recombinant surfactant protein d compositions and methods of use thereof

Номер: US20120010126A1

Автор: Howard Clark, Kenneth Bannerman Milne Reid, Palaniyar Nadesalingam, Peter Strong

Принадлежит: Medical Research Council

We describe an rspd(n/CRD) polypeptide, fragment, homologue, variant or derivative thereof for use in a method of treatment or prophylaxis of a disease. A method of treating an individual suffering from a disease or preventing the occurrence of a disease in an individual is also described, in which the method comprises administering to the individual a therapeutically or prophylactically effective amount of an rspd (n/CRD) polypeptide, fragment, homologue, variant or derivative thereof. Preferably, the rspd (n/CRD) polypeptide and nucleic acid comprise SEQ ID NO: 1 and SEQ ID NO: 2, respectively.

Подробнее

Номер записи: 23

12-01-2012 дата публикации

Tumor necrosis factor inhibiting peptides and uses thereof

Номер: US20120010158A1

Автор: Rahul Jain, Rajesh Jain, Shudhanand Prasad, Shweta Dubey, Vijay Goel, Virendra Kumar Vinayak

Принадлежит: Panacea Biotec Ltd

The present invention relates to Tumor Necrosis Factor-alpha (TNF-alpha or TNF-α) inhibiting peptides and process for the preparation thereof. The present invention further relates to a pharmaceutical composition comprising TNF-alpha inhibiting peptides of the present invention and uses thereof in treating TNF-alpha mediated inflammatory disorders.

Подробнее

Номер записи: 24

12-01-2012 дата публикации

5'-modified bicyclic nucleic acid analogs

Номер: US20120010393A1

Автор: Balkrishen Bhat, Eric E. Swayze, Punit P. Seth

Принадлежит: ISIS PHARMACEUTICALS INC

The present invention provides 5′-modified bicyclic nucleoside analogs and oligomeric compounds comprising at least one of these nucleoside analogs. In preferred embodiments the nucleoside analogs have either (R) or (S)-chirality at the 5′-carbon. These bicyclic nucleoside analogs are useful for enhancing properties of oligomeric compounds including for example enhanced nuclease resistance.

Подробнее

Номер записи: 25

12-01-2012 дата публикации

Orthopedic cement and use of same in radiation therapy

Номер: US20120010601A1

Автор: George Ding, Joseph Cheng, Scott D. Simon

Принадлежит: VANDERBILT UNIVERSITY

A method of treating diseased tissue in a patient, the diseased tissue being proximate a hardened previously implanted bone cement including relatively high atomic number elements in a patient. The method includes generating a photon beam and directing the generated photon beam into the patient in a direction such that at least a portion of the photon beam impinges on the hardened bone cement and generates Compton interaction knock-out electrons from the high atomic number elements included in the hardened bone cement as a result of interaction of the at least a portion of the photon beam with the bone cement, wherein the direction of the photon beam is such that the at least a portion of the photon beam impinges on the hardened bone cement so that at least some of the Compton interaction knock-out electrons impinge upon the diseased tissue.

Подробнее

Номер записи: 26

19-01-2012 дата публикации

Nucleic acid aptamers

Номер: US20120014875A1

Автор: Anton P. Mccaffrey, James O. McNamara, Paloma H. Giangrande

Принадлежит: University of Iowa Research Foundation UIRF

The present invention relates to optimized aptamers and methods of using these aptamers.

Подробнее

Номер записи: 27

19-01-2012 дата публикации

Il-1beta binding antibodies and fragments thereof

Номер: US20120014967A1

Автор: Arnold Horwitz, Gang Chen, Linda Masat, Marina Roell, Mary Haak-Frendscho

Принадлежит: Xoma Technology Ltd USA

An IL-1β binding antibody or IL-1β binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1β binding polypeptide. IL-1β binding antibodies or IL-1β binding fragments thereof are provided which have desirable affinity and potency.

Подробнее

Номер записи: 28

19-01-2012 дата публикации

PYRROLO[2,3-b]PYRIDIN-4-YL-AMINES AND PYRROLO[2,3-b]PYRIMIDIN-5-YL-AMINES AS JANUS KINASE INHIBITORS

Номер: US20120014989A1

Автор: Andrew P. Combs, Haisheng Wang, James D. Rodgers, Richard B. Sparks

Принадлежит: Incyte Corp

The present invention provides pyrrolo[2,3-b]pyridine-4-yl amines pyrrolo[2,3-b]pyrimidin-4-yl amines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases and cancer.

Подробнее

Номер записи: 29

19-01-2012 дата публикации

Complement receptor 2 targeted complement modulators

Номер: US20120015871A1

Автор: Stephen Tomlinson, V. Michael Holers

Принадлежит: MUSC Foundation for Research Development, University of Colorado

Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that are targeted to sites of complement activation and disease, compositions comprising a complement inhibitor linked to complement receptor (CR) 2 are disclosed. The disclosed are compositions can be used in methods of treating pathogenic diseases and inflammatory conditions by modulating the complement system.

Подробнее

Номер записи: 30

19-01-2012 дата публикации

Mek mutations conferring resistance to mek inhibitors

Номер: US20120015973A1

Автор: Carlos Garcia Echeverria, Caroline Emery, Levi A. Garraway

Принадлежит: Dana Farber Cancer Institute Inc, NOVARTIS AG

The present invention relates to methods, compositions and kits concerning resistance to treatment with an anti-cancer agent, specifically an inhibitor of MEK. In particular embodiments, the invention concerns mutations in a MEK sequence that confer resistance to a MEK inhibitor. Identification of such mutations in a MEK sequence allows the identification and design of second-generation MEK inhibitors. Methods and kits for detecting the presence of a mutant MEK sequence in a sample are also provided.

Подробнее

Номер записи: 31

19-01-2012 дата публикации

Sulfone Compounds Which Modulate The CB2 Receptor

Номер: US20120015988A1

Автор: Christopher Francis Palmer, David Smith Thomson, Doris Riether, Eugene Richard Hickey, Mark Whittaker, Monika Ermann, Patricia Amouzegh, Renee M. Zindell

Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Compounds which modulate the CB2 receptor are disclosed. Compounds according to the invention bind to and are agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally useful for treating pain.

Подробнее

Номер записи: 32

19-01-2012 дата публикации

Taspase1 inhibitors and their uses

Номер: US20120015990A1

Автор: Emily Cheng, James Hsieh

Принадлежит: Washington University in St Louis WUSTL

Provided herein are small molecule inhibitors of Taspase1 and methods of using the small molecule inhibitors of Taspase1 to treat neoplasm in subjects in need thereof.

Подробнее

Номер записи: 33

19-01-2012 дата публикации

Phototherapy methods and devices comprising emissive aryl-heteroaryl compounds

Номер: US20120015998A1

Автор: Amane Mochizuki, Brett T. Harding, Jensen Cayas, Keisaku Okada, Sazzadur Rahman Khan, SHENG Li, Shijun Zheng

Принадлежит: Nitto Denko Corp

Disclosed herein are compounds represented by a formula: R 1 —Ar 1 —X—Ar 2 —Ar 3 -Het, wherein R 1 , Ar 1 , X, Ar 2 , Ar 3 , and Het are described herein. Compositions and light-emitting devices related thereto are also disclosed.

Подробнее

Номер записи: 34

19-01-2012 дата публикации

RNAi MOLECULE TARGETING THYMIDYLATE SYNTHASE AND APPLICATION THEREOF

Номер: US20120016012A1

Автор: Cheng Long HUANG, Hiromi Wada

Принадлежит: Delta Fly Pharma Inc

This invention provides a novel RNAi molecule that can significantly potentiate antitumor effects of a 5-FU antitumor agent. The RNAi molecule comprises the nucleotide sequence shown in SEQ ID NO: 2. The invention also provides an antitumor agent comprising such RNAi molecule and a 5-FU antitumor agent.

Подробнее

Номер записи: 35

19-01-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer

Номер: US20120016019A1

Автор: Gee-Hwoon LEE

Принадлежит: Individual

The present invention relates to a compound of the formula I: wherein R is C 2 H 5 or C 2 H 3 , or a pharmaceutically acceptable salt or hydrate thereof, and a process for preparing said compound of the formula I. The invention also relates to the use of a composition comprising said compound of the formula I or a pharmaceutically acceptable salt or hydrate thereof as an active ingredient, for treating or preventing cancers.

Подробнее

Номер записи: 36

19-01-2012 дата публикации

Biphenyl compound selective agonists of gamma rar receptors

Номер: US20120016031A1

Автор: Etienne Thoreau, Thibaud Biadatti

Принадлежит: Galderma Research and Development SNC

Biphenyl compounds having the formula (I): are useful for preventing/treating pathologies linked to a deficiency of the activation of the RAR gamma receptor, e.g., for treating a pathology linked to a cell differentiation and/or proliferation disorder, for treating acne, for treating psoriasis.

Подробнее

Номер записи: 37

19-01-2012 дата публикации

Estrogen receptors and methods of use

Номер: US20120016109A1

Автор: Zhao Yi Wang

Принадлежит: CREIGHTON UNIVERSITY

The present invention provides isolated polypeptides having an amino acid sequence having at least 70% identity to SEQ ID NO:20, wherein the polypeptide has ER-α36 activity. The invention further provides methods for identifying agents that bind to such polypeptides, methods for detecting such polypeptides, and methods for altering the activity of such polypeptides. Also provided are antibodies that specifically bind to an amino acid sequence depicted at SEQ ID NO:1, or an immunogenic fragment thereof, and methods for making and using such antibodies.

Подробнее

Номер записи: 38

19-01-2012 дата публикации

Enzymes and methods for producing omega-3 fatty acids

Номер: US20120016144A1

Автор: Anne Maree Mackenzie, Craig Christopher Wood, Dion Matthew Frederick Frampton, James Robertson Petrie, Peter David Nichols, Peter Maged Mansour, Pushkar Shrestha, Qing Liu, Stanley Suresh Robert, Surinder Pal Singh, Susan Irene Ellis Blackburn, Xue-Rong Ziiou

Принадлежит: Individual

The present invention relates generally to the field of recombinant fatty acid synthesis, particularly in transgenic plants. The application describes genes involved in fatty acid synthesis and provides methods and vectors for the manipulation of fatty acid composition of plant oils. In particular, the invention provides constructs for achieving the integration of multiple heterologous genes involved in fatty acid synthesis into the plant genome, such that the resulting plants produce altered levels of polyunsaturated fatty acids. Also described are methods for enhancing the expression of fatty acid biosynthesis enzymes by co-expressing a silencing suppressor within the plant storage organ.

Подробнее

Номер записи: 39

26-01-2012 дата публикации

Process, composition and method for anion deposition into ferritin for therapeutic and other use

Номер: US20120020879A1

Автор: Richard K. Watt

Принадлежит: BRIGHAM YOUNG UNIVERSITY

Provided herein is a process for production of a metal nanoparticle, the process comprising providing a first solution containing a protein nanocage complex comprising a hydrophobic metal core and an ion-transport mechanism, providing a second solution containing a preselected anionic agent, combining the first and second solutions into a third combined solution, and applying an external method to the third combined solution to manipulate the metal core's redox state, in which reduction of the metal core causes the preselected anionic agent to be imported and incorporated into the metal core. Also provided herein is a composition from the process and a method of use.

Подробнее

Номер записи: 40

26-01-2012 дата публикации

MHC-Less cells

Номер: US20120020885A1

Автор: Edward K.Y. Jung, Elizabeth A. Sweeney, Eric C. Leuthardt, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Stephen L. Malaska, Wayne R. Kindsvogel

Принадлежит: SEARETE LLC

The present disclosure relates to compositions, methods, systems, computer-implemented methods, and computer program products thereof that relate to biological cells for delivery of at least one therapeutic agent to a biological tissue or subject.

Подробнее

Номер записи: 41

26-01-2012 дата публикации

Leukemia inhibitory factor (lif) for use in repressing human papillomavirus (hpv) transcription

Номер: US20120020914A1

Автор: Bruce K. Patterson, Joseph M. Bay, Nelson Teng

Принадлежит: Leland Stanford Junior University

Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF.

Подробнее

Номер записи: 42

26-01-2012 дата публикации

Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System

Номер: US20120020915A1

Автор: Ajay Gupta, Hyman M. Schipper, Jason Z. Vlahakis, Kanji Nakatsu, Moulay Alaoui-Jamali, Walter A. Szarek

Принадлежит: OSTA BIOTECHNOLOGIES Inc, Queens University at Kingston, Sir Mortimer B Davis Jewish General Hospita

Disclosed are compounds of the general formula (I): compositions comprising an effective amount of said compounds either alone or in combination with other chemotherapeutic agents, and methods useful for treating or preventing cancer and for inhibiting tumour tissue growth. These compounds attenuate the oxidative damage associated with increased heme-oxygenase activity and can reduce cell proliferation in transformed cells. In addition, the described compounds and compositions are useful as neuroprotectants and for treating or preventing neurodegenerative disorders and other diseases of the central nervous system.

Подробнее

Номер записи: 43

26-01-2012 дата публикации

Adverse side-effects associated with administration of anti-hyaluronan agents and methods for ameliorating or preventing the side-effects

Номер: US20120020951A1

Автор: Curtis Thompson, Gregory I. Frost, Harold Michael Shepard, Xiaoming Li

Принадлежит: Individual

Provided herein are methods for ameliorating an adverse effect of systemic administration of a PEG hyaluronan degrading enzyme to a subject. The methods involve systemically administering a PEGylated hyaluronan degrading enzyme, particularly a PEGylated hyaluronidase, such as any of the animal or bacterial hyaluronidases, to the subject and administering an amount of a corticosteroid sufficient to ameliorate the adverse effect. Also provided are method of treating a hyaluronan-associated disease or condition for single-agent therapy or combination therapy.

Подробнее

Номер записи: 44

26-01-2012 дата публикации

Methods and compositions for liver cancer therapy

Номер: US20120020961A1

Автор: Anne-Sophie Dume, Dominique Joubert, Frédéric HOLLANDE, Leïla Houhou

Принадлежит: Biorealites SAS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Institut National de la Sante et de la Recherche Medicale INSERM

The present disclosure provides methods of treating liver cancer and preventing liver cancer recurrence with anti-progastrin antibodies, methods of monitoring treatment efficacy of anti-progastrin therapy for liver cancer, and compositions useful therefore.

Подробнее

Номер записи: 45

26-01-2012 дата публикации

Antibodies against fatty acid synthase

Номер: US20120020978A1

Автор: Patrick J. Muraca

Принадлежит: Nuclea Biotechnologies Inc

The present invention relates to antibodies that immunospecifically bind to FAS and certain FAS related proteins. The invention encompasses human and humanized forms of the antibodies and their use in treating cancers and other proliferative disorders. The invention also relates to FAS-derived peptides useful for preparing the antibodies. Methods and compositions for detecting, diagnosing, treating or ameliorating a disease or disorder, especially cancer and other proliferative disorders using the present antibodies also are disclosed.

Подробнее

Номер записи: 46

26-01-2012 дата публикации

Garcinia Mangostana L. and Iridoid Based Formulations

Номер: US20120021079A1

Автор: Afa Kehaati Palu, Brett Justin West, Claude Jarakae Jensen, Jeffery A. Wasden, Shixin Deng

Принадлежит: Individual

Embodiments of the invention relate to fortified food and dietary supplement products, which may be administered to produce desirable physiological improvement. In particular, embodiments of the invention relate to the administration of products enhanced with Garcinia mangostana L. and iridoids.

Подробнее

Номер записи: 47

26-01-2012 дата публикации

Method of mitigating adverse drug events using omega-3 fatty acids as a parenteral therapeutic drug vehicle

Номер: US20120022001A1

Автор: David F. Driscoll

Принадлежит: STABLE SOLUTIONS LLC

A method of parenterally administering a composition, the method including parenterally administering to a person a composition including at least one omega-3 fatty acid and at least one drug, wherein the at least one omega-3 fatty acid source and the at least one drug are administered simultaneously.

Подробнее

Номер записи: 48

26-01-2012 дата публикации

Derivatives of n-(arylamino)sulfonamides as inhibitors of mek

Номер: US20120022076A1

Автор: Andreas Maderna, Dinesh Barawkar, Hassan El Abdellaoul, Jean-Michel Vernier, Varaprasad Chamakura, Zhi Hong

Принадлежит: Individual

This invention concerns N-(2-arylamino)aryl sulfonamides, which are inhibitors of MEK and are useful in treatment of cancer and other hyperproliferative diseases.

Подробнее

Номер записи: 49

26-01-2012 дата публикации

Compositions and methods for the treatment of pathological condition(s) related to gpr35 and/or gpr35-herg complex

Номер: US20120022116A1

Автор: Haibei Hu, Haiyan Sun, Huayun Deng, Mingqian He, Weijun Niu, YE Fang

Принадлежит: Corning Inc

Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treating diseases which are pathophysiologically related to GPR35 in a subject. The compounds having a formula (I), (II) or (III):

Подробнее

Номер записи: 50

26-01-2012 дата публикации

Heterocyclic antagonists of prostaglandin d2 receptors

Номер: US20120022119A1

Автор: Brian Andrew Stearns, Jeffrey Roger Roppe, John Howard Hutchinson, Nicholas Simon Stock, Timothy Parr

Принадлежит: Amira Pharmaceuticals Inc

Described herein are heteroaryl compounds that are antagonists of PGD 2 receptors. Also described are pharmaceutical compositions and medicaments that include the heteroaryl compounds described. Also described herein are methods of using such antagonists of PGD 2 receptors, alone and in combination with other compounds, for treating respiratory, cardiovascular, and other PGD2-dependent or PGD2-mediated conditions or diseases.

Подробнее

Номер записи: 51

26-01-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120022139A1

Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker

Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее

Номер записи: 52

26-01-2012 дата публикации

Recombinant Anti-VLA4 Antibody Molecules

Номер: US20120022236A1

Автор: Frank J. Carr, Philip R. Tempest, Roy R. Lobb

Принадлежит: BIOGEN IDEC MA INC

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Подробнее

Номер записи: 53

02-02-2012 дата публикации

Cancer therapy based on tumor associated antigens derived from cyclin d1

Номер: US20120027684A1

Автор: Harpreet Singh, Steffen Walter, Toni Weinschenk

Принадлежит: IMMATICS BIOTECHNOLOGIES GMBH

The present invention relates to cyclin D1-derived peptides for use in the improved treatment of cancer in a patient, particularly in the form of a combination therapy using a vaccine. Other aspects relate to the use of the peptides or a combination thereof as a diagnostic tool.

Подробнее

Номер записи: 54

02-02-2012 дата публикации

Hk1-binding proteins

Номер: US20120027686A1

Автор: Andrew Nixon, Anthony Williams, Daniel J. Sexton, Qi-Long Wu, Robert C. Ladner

Принадлежит: Dyax Corp

The invention features hK1 binding polypeptides as well as compositions comprising such polypeptides and methods of making and using such polypeptides.

Подробнее

Номер записи: 55

02-02-2012 дата публикации

Methods for treating adult respiratory distress syndrome

Номер: US20120027742A1

Автор: Jahar Bhattacharya, Sadiqa K. Quadri, Shonit Das

Принадлежит: Columbia University of New York

We have discovered that the activated phosphorylated form of focal adhesion kinase (hereafter “FAKp”) strengthens the microvascular endothelial cell (EC) junctions that form a barrier in pulmonary endothelia, and the increased barrier helps to prevent acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). Thus certain embodiments of the invention are directed to prevention and treatment of ALI and ARDS by administering a therapeutically effective amount of FAKp to subjects at risk of developing or diagnosed as having either ALI or ARDS.

Подробнее

Номер записи: 56

02-02-2012 дата публикации

Modified heparinase iii and methods of sequencing therewith

Номер: US20120027744A1

Автор: Dongfang Liu, Ganesh Venkataraman, Kevin Pojasek, Kristine Holley, Ram Sasisekharan, Yosuf El-Shabrawi, Zachary Shriver

Принадлежит: Massachusetts Institute of Technology

The invention relates to heparinase III and mutants thereof. Modified forms of heparinase III having reduced enzymatic activity which are useful for a variety of purposes, including sequencing of heparin-like glycosaminoglycans (HLGAGs), removing active heparan sulfate from a solution, inhibition of angiogenesis, etc. have been discovered according to the invention. The invention in other aspects relates to methods of treating cancer and inhibiting tumor cell growth and/or metastasis using heparinase III, or products produced by enzymatic cleavage by heparinase III of HLGAGs.

Подробнее

Номер записи: 57

02-02-2012 дата публикации

Method and compositions for cancer prognosis

Номер: US20120027750A1

Автор: Guillaume Cartron, Hervé WATIER

Принадлежит: Centre Hospitalier Regional Universitaire De Tours, UNIVERSITE FRANCOIS RABELAIS DE TOURS

Methods are provided to determine the cancer prognosis of subjects and/or to adapt the treatment protocol of subjects having or susceptible to cancer. Embodiments include the steps of determining in vitro the genotype of said subject at a polymorphism in the C3-ITGAM axis, making a cancer prognosis of the subject based on said genotype and selecting an anti-cancer treatment for the subject.

Подробнее

Номер записи: 58

02-02-2012 дата публикации

Induction of p53 expression by neutralization of neuropilin-2 for the treatment of cancers

Номер: US20120027779A1

Автор: Camille Grandclement, Christophe Borg, John Wijdenes

Принадлежит: Diaclone SAS, EFS Bourgogne Franche Comte, Université de Franche-Comté

The present invention relates to the use of anti-human neuropilin-2 antibodies, or of ligands of human neuropilin-2 derived from these antibodies, for obtaining a medicament intended to increase p53 expression and to induce tumour cell apoptosis in the context of an anticancer treatment.

Подробнее

Номер записи: 59

02-02-2012 дата публикации

Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)

Номер: US20120027782A1

Автор: Chetana Rao-Naik, Chin Pan, Jonathan Alexander Terrett

Принадлежит: Bristol Myers Squibb Co

The present disclosure relates to antibody-partner molecule conjugates directed to PTK7. Also described are methods for treating or preventing a disease characterized by growth of tumor cells expressing PTK7 using the antibody-partner molecule conjugates.

Подробнее

Номер записи: 60

02-02-2012 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: US20120027796A1

Автор: David Butler, Jayaprakash K. Narayanannair, Kallanthottathil G. Rajeev, Laxmab Eltepu, Muthiah Manoharan, Muthusamy Jayaraman

Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV)).

Подробнее

Номер записи: 61

02-02-2012 дата публикации

Antibody gene transfer and recombinant aav therefor

Номер: US20120027798A1

Автор: Kelly Reed Clark, Philip R. Johnson, Jr.

Принадлежит: Nationwide Childrens Hospital Inc

The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver antibody genes to target cells in mammals. Administration of rAAV encoding antibodies that neutralize the HIV-1 virus is exemplified.

Подробнее

Номер записи: 62

02-02-2012 дата публикации

Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer

Номер: US20120027799A1

Автор: Cynthia L. Sears, Drew M. Pardoll, Franck Housseau, Shaoguang Wu

Принадлежит: JOHNS HOPKINS UNIVERSITY

The invention provides compositions and methods for useful for the diagnosis of inflammatory bowel disease, ETBF-induced colitis, colonic hyperplasia and/or colon carcinogenesis in a subject in biological samples (e.g., stool, urine, blood, serum, tissue). The invention further provides compositions and methods for the treatment or prevention of colitis, colon cancer, or inflammatory bowel disease (e.g., Crohn's disease).

Подробнее

Номер записи: 63

02-02-2012 дата публикации

Nicotine immunonanotherapeutics

Номер: US20120027808A1

Автор: Matteo Iannacone

Принадлежит: Brigham and Womens Hospital Inc, Harvard College, Massachusetts Institute of Technology

The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides nanocarriers capable of stimulating an immune response in T cells and/or in B cells. The invention provides nanocarriers that comprise an immunofeature surface having a plurality of nicotine moieties. The invention provides pharmaceutical compositions comprising nanocarriers. The present invention provides methods of designing, manufacturing, and using nanocarriers and pharmaceutical compositions thereof. For example, the present invention describes nanocarriers capable of eliciting an immune response and the production of anti-nicotine antibodies.

Подробнее

Номер записи: 64

02-02-2012 дата публикации

Bisphosphonate product in a cycloolefinic polymer container

Номер: US20120027818A1

Автор: Alexandra Glausch, Juergen Sigg, Rolf Loeffler

Принадлежит: Individual

A pharmaceutical product comprises a container containing a bisphosphonate solution, in which at least the internal surface of the container comprises a plastic material and in which the container is heat sterilisable, and which is in the form of an infusion solution preconcentrate for administration of the bisphosphonate to a patient in need of bisphosphonate treatment.

Подробнее

Номер записи: 65

02-02-2012 дата публикации

Apj receptor compounds

Номер: US20120028888A1

Автор: Athan Kuliopulos, Jay Janz, Thomas J. Mcmurry

Принадлежит: ANCHOR THERAPEUTICS Inc

The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection.

Подробнее

Номер записи: 66

02-02-2012 дата публикации

Isolation, Purification, and Structure Elucidation of the Antiproliferative Compound Coibamide A

Номер: US20120028905A1

Автор: Douglas Eugene Goeger, Kerry Leigh McPhail, Rebecca Ann Medina, Todd Leo Capson, William Henry Gerwick

Принадлежит: Oregon State, Oregon State Board of Higher Education, Smithsonian Tropical Research Institute, University of California San Diego UCSD

Novel antiproliferative compounds, compositions comprising the same, and methods of use thereof are disclosed.

Подробнее

Номер записи: 67

02-02-2012 дата публикации

Natural marine source phospholipids comprising polyunsaturated fatty acids and their applications

Номер: US20120028922A1

Автор: Fotini Sampalis

Принадлежит: Individual

A phospholipid extract from a marine or aquatic biomass possesses therapeutic properties. The phospholipid extract comprises a variety of phospholipids, fatty acid, metals and a novel flavonoid.

Подробнее

Номер записи: 68

02-02-2012 дата публикации

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Номер: US20120028925A1

Автор: Andrew J. Souers, Gerard M. Sullivan, Nathaniel D. Catron, Xilu Wang, Zhi-Fu Tao

Принадлежит: ABBOTT LABORATORIES

Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.

Подробнее

Номер записи: 69

02-02-2012 дата публикации

Pyrazole compounds as crth2 antagonists

Номер: US20120028938A1

Автор: Christoph Hoenke, Dieter Wolfgang Hamprecht, Domnic Martyres, Peter Seither, Ralf Anderskewitz, Thorsten Oost, Wolfgang Rist

Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

The present invention relates to pyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof having CRTH2-activity, wherein W, L 1 , L 2 , X, L 3 , Y, R 1 and R 2 are as defined in the specification and claims, to their use as medicaments and to pharmaceutical formulations, containing said compounds or containing a combination of said compounds with one or more active substances.

Подробнее

Номер записи: 70

02-02-2012 дата публикации

Biomarker assays for detecting or measuring inhibition of tor kinase activity

Номер: US20120028972A1

Автор: Jian-hua DING, Lilly Wong, Shuichan Xu

Принадлежит: Signal Pharmaceuticals LLC

Provided herein are methods for detecting and/or measuring the inhibition of TOR kinase activity in a subject and uses associated therewith.

Подробнее

Номер записи: 71

02-02-2012 дата публикации

Compounds Effective Against Cancer

Номер: US20120028993A1

Автор: Ingo Schmidt-Wolf

Принадлежит: Individual

The present invention describes a Composition, comprising one or more compounds selected from the group consisting of a) compound (I) which is ethacrynic acid bezafibrate, fenofibrate, and/or griseofulvin, b) compound (II), which is ciclopirox ciclopirox olamine, octopirox, and/or cinnarizine, c) mixtures of compound (I) and compound (II), or pharmaceutically acceptable derivatives thereof for the treatment of cancer. The present invention is further directed to the use of said compounds or a mixture of compounds for the manufacture of a medicament for the treatment of cancer and to the use of said compound in a method for treating cancers in animals and humans.

Подробнее

Номер записи: 72

02-02-2012 дата публикации

Nitroxide Free Radical Synergized Antineoplastic Agents

Номер: US20120029021A1

Автор: Errol V. Mathias, Yong Ba

Принадлежит: California State University

Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration.

Подробнее

Номер записи: 73

02-02-2012 дата публикации

Clonidine for treatment of bone cancer

Номер: US20120029042A1

Автор: Vanja Margareta King

Принадлежит: WARSAW ORTHOPEDIC INC

The present invention is directed to a method for treating osteolytic bone cancer. The method comprises implanting a drug depot locally at or near the osteolytic bone cancer, wherein the drug depot comprises at least one biodegradable polymer and clonidine in an amount from about 0.1 wt. % to about 30 wt. % of the drug depot.

Подробнее

Номер записи: 74

02-02-2012 дата публикации

Crystalline form of sunitinib and processes for its preparation

Номер: US20120029046A1

Автор: Bharati Choudhari, Mahesh Hublikar, Prakash Bansode, Vinayak Gore

Принадлежит: Generics UK Ltd

The present invention relates to a novel crystalline form of sunitinib free base designated form I and to processes for its preparation. The invention also relates to its use as an API and in the preparation of various forms of sunitinib. Further, the invention relates to pharmaceutical compositions comprising the novel crystalline form and salts, solvates and hydrates prepared according to the invention, and to the uses of said pharmaceutical compositions in the treatment and/or prevention of cancer.

Подробнее

Номер записи: 75

02-02-2012 дата публикации

Short Interfering Ribonucleic Acid (siRNA) for Oral Administration

Номер: US20120029052A1

Автор: Christian Rene Schnell, Eric Billy, Francois Jean-Charles Natt, Juerg Hunziker

Принадлежит: NOVARTIS AG

Short interfering ribonucleic acid (siRNA) for oral administration, said siRNA comprising two separate RNA strands that are complementary to each other over at least 15 nucleotides, wherein each strand is 49 nucleotides or less, and wherein at least one of which strands contains at least one chemical modification.

Подробнее

Номер записи: 76

02-02-2012 дата публикации

Pharmaceutical compositions containing fluorinated or perfluorinated carboxylic acids

Номер: US20120029079A1

Автор: Charles R. Wolf, Clifford R. Elcombe

Принадлежит: CXR Biosciences Ltd

The molecules of formula (I) are useful in treating diabetes, obesity, hypercholesterolaemia, hyperlipidaemia, cancer, inflammation or other conditions in which modulation of lipis of eicosanoid status or functions may be desirable. Formula (I): Z 1 —Z 1 —Z 2 wherein a) Z 1 represents CO 2 H or a derivative thereof; b) Z 2 represents F, H, —CO 2 H or a derivative thereof; and c) X represents fluorinated alkylene; or a solvate thereof, for example a perfluorinated fatty acid or derivative thereof.

Подробнее

Номер записи: 77

09-02-2012 дата публикации

Tyrosine kinase receptor tyro3 as a therapeutic target in the treatment of cancer

Номер: US20120034167A1

Автор: François RADVANYI, Isabelle Bernard-Pierrot, Nicolas Stransky, Yves Allory

Принадлежит: Assistance Publique Hopitaux de Paris APHP, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, INSTITUT CURIE, Universite Paris Est Creteil Paris 12

The present invention concerns new methods for treating cancer by using TYRO3 inhibitors and methods for identifying new molecules of interest for treating cancer.

Подробнее

Номер записи: 78

09-02-2012 дата публикации

Treatment of neurotrophic factor mediated disorders

Номер: US20120034193A1

Автор: Antonia Orsi, Daryl Rees, Patrick Howson, Yaer Hu, Zongqin Xia

Принадлежит: Phytopharm Ltd

An agent selected from A/B-cis furostane, furostene, spirostane and spirostene steroidal sapogenins and ester, ether, ketone and glycosylated forms thereof is used to induce self-regulated homeostasis of neurotrophic factors (NFs), for example BDNF and/or GDNF, NFs with limited and manageable side effects in a subject, by modulating NFs in a non-toxic manner under homeostatic control. An effective amount of at least one such agent is administered to the subject, particularly in the treatment or prevention of a range of NF-mediated disorders, particularly neurological, psychiatric, inflammatory, allergic, immune and neoplastic disorders, and in the restoration or normalisation of neuronal and other function in or in relation to any damaged or abnormal tissue, including when assisting tissue (for example, skin, bone, eye and muscle) healing and general skin, bone, eye and muscle health.

Подробнее

Номер записи: 79

09-02-2012 дата публикации

Compositions for potentiating apoposis signals in tumour cells

Номер: US20120034210A1

Автор: Anne-Marie Vacher, Benjamin Chaigne-Delalande, Laurence Bepoldin, Patrick Legembre, Pierre Soubeyran, Pierre Vacher

Принадлежит: Institut Bergonié, Universite Victor Segalen Bordeaux 2

The present invention concerns a composition for potentiating formation of DISC (Death Inducing Signaling Complex) macro-complex and for inducing apoptotic signal mediated by death receptors in tumour cells comprising a therapeutically effective amount of an active agent selected among a hypocalcemia-inducing agent, a calcium channel inhibitor and a calcium chelator in association with a therapeutically effective amount of an anticancer agent inducing an apoptotic signal via death receptors Fas, TNF-R1, DR4 and/or DR5.

Подробнее

Номер записи: 80

09-02-2012 дата публикации

Marker for Liver-Cancer Diagnosis and Recurrence and Survival Prediction, a Kit Comprising the Same, and Prognosis Prediction in Liver-Cancer Patients Using the Marker

Номер: US20120034235A1

Автор: Chul Ju Han, Dong Hyoung Lee, Eun Ju LEE, Eun Ran Park, Hyun Jin Shin, Kee Ho Lee, Myoung Jin Park, Pu Hyeon Cha, Sang Bum Kim, Sang Gu Hwang, Seon Rang Woo, Sun Hoo Park, Yong Ho Ham

Принадлежит: Korea Institute of Radiological and Medical Sciences

A composition for detecting a marker for the diagnosis or prognosis of liver cancer is disclosed. The composition includes an agent capable of assessing the expression level of UQCRH (ubiquinol-cytochrome c reductase hinge protein). In addition, a kit having the composition, a microarray for the diagnosis of liver cancer using the marker, and a method for detecting the marker, and predicting recurrence following surgery in liver cancer patients are disclosed. The marker is able to contribute to the early diagnosis of liver cancer and prediction of recurrence following surgery and survival of liver cancer patients who have undergone hepatic resection, and also is significant for being a promising therapeutic target for liver cancer.

Подробнее

Номер записи: 81

09-02-2012 дата публикации

Methods of treating secondary bone tumors with antibodies against pdgfr alpha

Номер: US20120034244A1

Автор: Alessandro FATATIS, Nathan Graeme DOLLOFF, Nick LOIZOS

Принадлежит: ImClone LLC, Philadelphia Health and Education Corp

The invention provides methods of treating bone cancer, particularly metastatic bone cancer, by administering an IGF-IR antagonist and/or a PDGFRα antagonist. The invention also provides antibodies that bind to human PDGFRα and neutralize activation of the receptor. The invention further provides a methods for neutralizing activation of PDGFRα, and a methods of treating a mammal with a neoplastic disease using the antibodie alone or in combination with other agents.

Подробнее

Номер записи: 82

09-02-2012 дата публикации

Pharmaceutical composition for treating or preventing cancer by inducing dendritic cell-like differentiation from monocytes to improve anticancer immune activity

Номер: US20120034251A1

Автор: Hiromi Kumon, Masami Watanabe, Yasutomo Nasu, Yuji Kashiwakura

Принадлежит: Momotaro Gene Inc

According to the present invention, a composition for inducing or activating dendritic cell-like cells so as to treat or prevent cancer by immunotherapy is provided. Specifically, the following is provided: an agent for activating cancer immunity, which comprises, as an active ingredient, the following REIC protein: (a) a protein consisting of the amino acid sequence shown in SEQ ID NO: 2; or (b) a protein consisting of an amino acid sequence derived from the amino acid sequence shown in SEQ ID NO: 2 by substitution, deletion, or addition of one or more amino acid(s) and having the activity of inducing differentiation from monocytes into dendritic cell-like cells.

Подробнее

Номер записи: 83

09-02-2012 дата публикации

Cell lines producing blocking antibodies to human RANKL

Номер: US20120034690A1

Автор: Dirk M. Anderson

Принадлежит: Immunex Corp

Described herein are cell lines and methods for preparing antibodies that bind RANKL, including cell lines that produce blocking antibodies to human RANKL.

Подробнее

Номер записи: 84

09-02-2012 дата публикации

Neuronal differentiation-inducing peptide and use thereof

Номер: US20120035112A1

Автор: Nahoko Kobayashi, Tetsuhiko Yoshida

Принадлежит: TOAGOSEI CO LTD

A neuronal differentiation inducer provided by the present invention contains an artificially synthesized peptide which includes an amino acid sequence constituting a signal peptide in amyloid precursor protein (APP), or a partial sequence of the amino acid sequence constituting this signal peptide.

Подробнее

Номер записи: 85

09-02-2012 дата публикации

Glycolipids as treatment for disease

Номер: US20120035120A1

Автор: Shawn Defrees

Принадлежит: Seneb Biosciences Inc

This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.

Подробнее

Номер записи: 86

09-02-2012 дата публикации

Ophthalmic compositions and methods for treating ophthalmic conditions

Номер: US20120035148A1

Автор: Scott M. Whitcup

Принадлежит: Allergan Inc

Compositions, and methods of using such compositions, useful for placement, for example injection, into the interior of human or animal eyes are provided. Such compositions include a therapeutic component, such as one or more corticosteroids, a biocompatible polymeric component, and a solvent component.

Подробнее

Номер записи: 87

09-02-2012 дата публикации

Substituted dihydropyrazolones and their use

Номер: US20120035151A1

Автор: Friederike Stoll, Hartmut Beck, Ingo Flamme, Mario Jeske, Metin Akbaba

Принадлежит: Bayer Pharma AG

The present application relates to novel substituted dihydropyrazolone derivatives, processes for their preparation, their use for treatment and/or prophylaxis of diseases and their use for the preparation of medicaments for treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Подробнее

Номер записи: 88

09-02-2012 дата публикации

Modulators of Cellular Adhesion

Номер: US20120035154A1

Автор: Johan D. Oslob, Kenneth Barr, Min Zhong, Wang Shen

Принадлежит: Sarcode Bioscience Inc

The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

Подробнее

Номер записи: 89

09-02-2012 дата публикации

Pharmaceutical composition for treating cancer comprising chlorin e6-folic acid conjugate compound and chitosan

Номер: US20120035180A1

Автор: Eun Hee Lee, Hyo Jun Kim, Kye Shin Park

Принадлежит: Diatech Korea Co Ltd

The present invention relates to a pharmaceutical composition for the treatment of cancer comprising a chlorin e6-folic acid conjugate compound and chitosan, and more particularly, to a pharmaceutical composition for photodynamic therapy of solid tumors comprising the novel chlorin e6-folic acid conjugate compound or a pharmaceutically acceptable salt thereof and chitosan, in which the novel compound is prepared by linking chlorin e6 to folic acid, and effectively produces singlet oxygen in various media and has much better tumor selectivity than the known porphyrin-based photosensitizers, thereby being used effectively in photodynamic treatment for malignant tumors.

Подробнее

Номер записи: 90

09-02-2012 дата публикации

Preparation and application of novel antibacterial and anticancer compounds and their derivatives

Номер: US20120035206A1

Автор: Baoling Fang, Chunliu Yang, Ge Wang, Gengliang YANG, Ligai Bai, Linbo Li, WEI Tian, Zhengyue Ma

Принадлежит: Individual

Novel antibiotic and anticancer compounds of formula I, II, III, IV, derivatives, ostereoisomer, racemic and noracemic mixture of ostereoisomer, or the pharmaceutically acceptable salts or solvates of these compounds are disclosed. The preparation, pharmaceutical composition and biological activity of these compounds are disclosed.

Подробнее

Номер записи: 91

09-02-2012 дата публикации

Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging

Номер: US20120035250A1

Автор: Dayan Goodenowe, M. Amin Khan, Paul L. Wood, Pearson Ahiahonu, Rishikesh Mankidy

Принадлежит: Phenomenome Discoveries Inc

Described herein are routes of synthesis and therapeutic uses of 1-alkyl, 2-acyl glycerol derivatives of formula I: which when administered to mammalian biological systems result in increased cellular concentrations of specific sn-2 substituted ethanolamine plasmalogens independent of the ether lipid synthesis capacity of the system. Elevating levels of the specific sn-2 substituted species in this way can cause lowering of membrane cholesterol levels and the lowering of amyloid secretion. These compounds can be used for the treatment or prevention of diseases of aging associated with increased membrane cholesterol, increased amyloid, and decreased plasmalogen levels, such as neurodegeneration (including Alzheimer's disease, Parkinson's disease and age-related macular degeneration), cognitive impairment, dementia, cancer (e.g. prostate, lung, breast, ovarian, and kidney cancers), osteoporosis, bipolar disorder and vascular diseases (such as atherosclerosis, hypercholesterolemia).

Подробнее

Номер записи: 92

09-02-2012 дата публикации

Sphingo-guanidines and their use as inhibitors of sphingosine kinase

Номер: US20120035268A1

Автор: Alicja Bielawska, James Norris, Lina M. Obeld, LIU Xiang, Yusuf A. Hannun, Zdzislaw M. Szulc

Принадлежит: Medical University of South Carolina (MUSC)

The presently disclosed subject matter provides compounds of the formula: (1) and pharmaceutically acceptable salts thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined herein. Also disclosed are methods for making the compounds of the formula as set forth hereinabove, their use in inhibiting sphingosine kinase, and their use in the treatment and/or prevention of diseases and/or conditions associated with undesirable ceramidase or sphingosine kinase activity, including, but not limit cancer, cancer metastasis, atherosclerosis, stenosis, inflammation, immunological disorders, asthma, atopic dermatitis, wound healing, and other proliferative diseases.

Подробнее

Номер записи: 93

09-02-2012 дата публикации

Compounds useful as inhibitors of atr kinase

Номер: US20120035407A1

Автор: Jean-Damien Charrier, Michael O'donnell, Philip Michael Reaper, Ronald Marcellus Alphonsus Knegtel, Steven John Durrant

Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula II: wherein the variables are as defined herein.

Подробнее

Номер записи: 94

16-02-2012 дата публикации

Compositions and methods for diagnosing prostate cancer based on detection of slc45a3-elk4 fusion transcript

Номер: US20120039887A1

Автор: David S. Rickman, Dorothee Pflueger, Mark A. Rubin

Принадлежит: CORNELL UNIVERSITY

RNA transcripts representing a fusion of a human SLC45A3 nucleic acid and a human ELK4 nucleic acid that are associated with prostate cancer are described. Compositions and methods useful for detection of fusion transcripts of human SLC45A3 and ELK4 genetic sequences associated with cancer and useful for cancer therapy are provided.

Подробнее

Номер записи: 95

16-02-2012 дата публикации

Glioblastoma multiforme-reactive antibodies and methods of use thereof

Номер: US20120039915A1

Автор: Bin Liu, James D. Marks, Scott Bidlingmaier, Xiaodong Zhu

Принадлежит: UNIVERSITY OF CALIFORNIA

The present disclosure is generally related to antibodies that bind specifically to glioblastoma multiforme (GBM) cells. In particular, the present disclosure provides compositions comprising human single chain or full-length antibodies that bind tumor cells. Additionally the present disclosure provides methods of using the anti-GBM antibodies.

Подробнее

Номер записи: 96

16-02-2012 дата публикации

Intergenic regions as insertion sites in the genome of modified vaccinia virus ankara (mva)

Номер: US20120039936A1

Автор: Paul Howley, Sonja Leyrer

Принадлежит: Individual

The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into said new insertion site as medicine or vaccine.

Подробнее

Номер записи: 97

16-02-2012 дата публикации

RBM3 in Testicular Cancer Diagnostics and Prognostics

Номер: US20120040338A1

Автор: Jakob Eberhard, Karin Jirstrom

Принадлежит: Atlas Antibodies AB

The present disclosure provides a method for determining whether a mammalian subject belongs to a first or a second group, wherein subjects of the first group have a higher risk of having a testicular disorder than subjects of the second group, comprising the steps of: evaluating an amount of RBM3 protein or RBM3 mRNA in at least part of an earlier obtained sample comprising biological material from a testicle of said subject and determining a sample value corresponding to the evaluated amount; comparing said sample value with a predetermined reference value; and if said sample value is higher than said reference value, concluding that the subject belongs to the first group; and if said sample value is lower than or equal to said reference value, concluding that the subject belongs to the second group. Further, a prognostic method for testicular cancer is provided, as well as means and uses with prognostic and diagnostic applications.

Подробнее

Номер записи: 98

16-02-2012 дата публикации

Identification of novel antagonist toxins of t-type calcium channel for analgesic purposes

Номер: US20120040909A1

Автор: Emmanuel Bourinet, Fabrice Marger, Joël Nargeot, Michel Lazdunski, Pierre Escoubas

Принадлежит: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, Universite de Nice Sophia Antipolis UNSA

A peptide with the following sequence YCQKFLWTCDSERPCCEGLVCRLWCKIN (SEQ ID NO 1) or a derivative thereof, and nucleic acids coding for the peptide having the sequence (SEQ ID NO 1). Also the use of this peptide as an antagonist and/or reverse agonist of T-type calcium channels. A use of the peptide for preparing a drug, in particular an analgesic one.

Подробнее

Номер записи: 99

16-02-2012 дата публикации

Methods and compositions for inhibiting cellular proliferation and surgical adhesion

Номер: US20120040928A1

Автор: Rekha Bansal

Принадлежит: Rekha Bansal

A method for inhibiting cellular proliferation of fibroblasts and/or blioma cells in a mammal includes administering a composition to a mammal wherein the composition includes an amount of an anionic polymer and an anti-platelet agent effective to inhibit cellular proliferation of fi- broblasts and gliomas in the mammal

Подробнее

Номер записи: 100

Настройки

Небесная энциклопедия

Мониторинг СМИ

Форма поиска